Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment

被引：0
|
作者：
P. D. Miller
E. N. Schwartz
P. Chen
D. A. Misurski
J. H. Krege
机构：
[1] University of Colorado Health Sciences Center & Colorado Center for Bone Research,Department of Medicine
[2] Northern California Institute for Bone Health,Lilly Research Laboratories
[3] Eli Lilly and Company,undefined
来源：
Osteoporosis International | 2007年 / 18卷
关键词：
Adverse events; Bone mineral density; Fragility fracture; Osteoporosis; Renal impairment; Teriparatide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：59 / 68
页数：9
相关论文
共 50 条
  • [41] Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis
    Kawada, T.
    OSTEOPOROSIS INTERNATIONAL, 2014, 25 (09) : 2321 - 2321
  • [42] EFFECT OF TERIPARATIDE IN CHINESE AND CAUCASIAN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: BRIDGING FINDINGS ON EFFICACY
    Li, M.
    Gurbuz, S.
    Chen, Y.
    Zhang, B.
    Li, Y. J.
    Chen, Y.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 : S216 - S216
  • [43] The comparative effect of teriparatide and denosumab on activins, follistatins, and inhibins in women with postmenopausal osteoporosis
    Anastasilakis, Athanasios D.
    Polyzos, Stergios A.
    Makras, Polyzois
    Savvidis, Matthaios
    Mantzoros, Christos S.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2024, 39 (09) : 1306 - 1314
  • [44] Analyzing the factors associated with efficacy among teriparatide treatment in postmenopausal women with osteoporosis
    Meng Kong
    Changtong Gao
    Xiaona Luan
    Cuiying Fan
    Meng Hao
    Canghai Jin
    Jiangning Zhao
    Hongyan Li
    Jindong Zhao
    Jian Luan
    Yong Lin
    Qiang Li
    BMC Musculoskeletal Disorders, 25
  • [45] Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis
    Hwang, JS
    Tu, ST
    Yang, TS
    Chen, JF
    Wang, CJ
    Tsai, KS
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 (03) : 373 - 378
  • [46] Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis
    Lindsay, R.
    Miller, P.
    Pohl, G.
    Glass, E. V.
    Chen, P.
    Krege, J. H.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 (06) : 943 - 948
  • [47] Teriparatide Accelerates Lumbar Posterolateral Fusion in Women With Postmenopausal Osteoporosis Prospective Study
    Ohtori, Seiji
    Inoue, Gen
    Orita, Sumihisa
    Yamauchi, Kazuyo
    Eguchi, Yawara
    Ochiai, Nobuyasu
    Kishida, Shunji
    Kuniyoshi, Kazuki
    Aoki, Yasuchika
    Nakamura, Junichi
    Ishikawa, Tetsuhiro
    Miyagi, Masayuki
    Kamoda, Hiroto
    Suzuki, Miyako
    Kubota, Gou
    Sakuma, Yoshihiro
    Oikawa, Yasuhiro
    Inage, Kazuhide
    Sainoh, Takeshi
    Takaso, Masashi
    Ozawa, Tomoyuki
    Takahashi, Kazuhisa
    Toyone, Tomoaki
    SPINE, 2012, 37 (23) : E1464 - E1468
  • [48] Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis
    T. Kawada
    Osteoporosis International, 2014, 25 : 2321 - 2321
  • [49] Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study
    Mei Li
    Zhenlin Zhang
    Qingyun Xue
    Qifu Li
    Xiaolan Jin
    Jin Dong
    Qun Cheng
    Li You
    Hua Lin
    Hai Tang
    Lin Shen
    Xin Gao
    Ji Hu
    Aijun Chao
    Pengqiu Li
    Rui Shi
    Shuhui Zheng
    Ying Zhang
    Xiaojiang Xiong
    Wei Yu
    Weibo Xia
    Archives of Osteoporosis, 2022, 17
  • [50] Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study
    Li, Mei
    Zhang, Zhenlin
    Xue, Qingyun
    Li, Qifu
    Jin, Xiaolan
    Dong, Jin
    Cheng, Qun
    You, Li
    Lin, Hua
    Tang, Hai
    Shen, Lin
    Gao, Xin
    Hu, Ji
    Chao, Aijun
    Li, Pengqiu
    Shi, Rui
    Zheng, Shuhui
    Zhang, Ying
    Xiong, Xiaojiang
    Yu, Wei
    Xia, Weibo
    ARCHIVES OF OSTEOPOROSIS, 2022, 17 (01)
12345